Momenta Pharmaceuticals, Inc.
Oct 11, 2006

Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2006 Financial Results

CAMBRIDGE, Mass., Oct. 11 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, will report its financial results for the third quarter ended September 30, 2006 before the U.S. financial markets open on Friday, November 3, 2006.

Management will host a conference call on that date at 10:00 am EST to discuss these results and provide an update on the company. To access the call, please dial 866-277-1182 (domestic) or 617-597-5359 (international) prior to the scheduled conference call time and provide the access code 34891236. A replay of the call will be available approximately two hours after the call and will be accessible through November 10, 2006. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and provide the access code 57492714.

A live audio webcast of the call will be available on the "Investors" section of the Company's website, http://www.momentapharma.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call and will be available through December 3, 2006.

About Momenta:

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed characterization and engineering of complex sugars. Momenta is applying its technology to create technology-enabled generic versions of sugar-based and other complex drug products, develop improved versions of existing drugs, and discover novel drugs and new biological processes. The Company's most advanced product candidate is M-Enoxaparin, a technology- enabled generic version of Lovenox®. Momenta's first improved drug candidate is M118, a rationally engineered anticoagulant specifically designed for acute coronary syndromes. The Company is developing other novel drug candidates through its discovery effort focused on understanding sugar-based biological processes. Momenta was founded in 2001 based on technology initially developed at Massachusetts Institute of Technology and is headquartered in Cambridge, MA.

To receive additional information about Momenta, please visit the website at http://www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Contact:
Michael A. Lawless
Momenta Pharmaceuticals, Inc.
617-395-5189

SOURCE Momenta Pharmaceuticals